Spero Therapeutics, Inc. (SPRO) Dividend History

Company News

• Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

  Spero Therapeutics announced interim leadership changes, including the appointment of Esther Rajavelu as Interim President and CEO, and Frank Thomas as Chairman of the Board. The company also provided updates on the Phase 3 PIVOT-PO trial of Tebipenem HBr and its financial position.

  GlobeNewswire Inc.
• Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

  Spero Therapeutics, a biopharmaceutical company, announced the grant of 227,500 restricted stock unit awards to new employees under its 2019 Inducement Equity Incentive Plan. The RSUs will vest over four years, subject to continued employment.

  GlobeNewswire Inc.
• Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?

  Denali Therapeutics (DNLI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

  Zacks Investment Research

  Featured Companies: DNLI
• Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 28, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of 116,667 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The RSUs are being granted as an inducement material to the new employee becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4).

  GlobeNewswire Inc.
• Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

  CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, to take place on Monday, May 20, 2024, at the NASDAQ World Headquarters New York, NY. Details are as follows:

  GlobeNewswire Inc.